Abstract
Purpose: To investigate whether subfoveal choroidal thickness predicted treatment response to anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Methods: This retrospective observational case series included 66 eyes of 60 patients who were diagnosed with new-onset PCV and who were followed for a minimum of 6 months. Patients received three monthly intravitreal injections of 0.5 mg ranibizumab or 1.25 mg bevacizumab, at baseline, month 1, and month 2. “Good responders” were defined as those who showed complete resolution of subretinal and/or intraretinal fluid at month 3 after the loading injections, whereas “poor responders” were defined as those who showed persistent retinal fluid on optical coherence tomography (OCT) at month 3 after treatment. Differences in best-corrected visual acuity, indocyanine green angiography, and spectral domain-OCT findings at baseline were analyzed between the two groups. Results: The mean patient age was 68.2 ± 9.7 years, and the mean follow-up period was 27 ± 21 months. The mean subfoveal choroidal thickness was 273 ± 117 μm, and choroidal vascular hyperpermeability was observed in 35 eyes (53.0 %). Thirty-three eyes (50 %) showed good response to treatment, and a thinner subfoveal choroid at baseline significantly correlated with favorable treatment response (P = 0.024). However, there was no significant relationship between treatment response and choroidal vascular hyperpermeability (P = 0.999). Conclusions: The subfoveal choroid was found to be significantly thinner among patients who achieved complete resolution of macular exudation after three loading injections of anti-VEGF agents.
| Original language | English |
|---|---|
| Pages (from-to) | 1497-1503 |
| Number of pages | 7 |
| Journal | Graefe's Archive for Clinical and Experimental Ophthalmology |
| Volume | 254 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2016 Aug 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Ophthalmology
- Sensory Systems
- Cellular and Molecular Neuroscience
Cite this
}
Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. / Kim, Hyesun; Lee, Sungchul; Kwon, Kye Yoon; Lee, Ji Hwan; Koh, Hyoung Jun; Byeon, Suk Ho; Kim, Sung Soo; Kim, Min; Lee, Christopher Seungkyu.
In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 254, No. 8, 01.08.2016, p. 1497-1503.Research output: Contribution to journal › Article
TY - JOUR
T1 - Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy
AU - Kim, Hyesun
AU - Lee, Sungchul
AU - Kwon, Kye Yoon
AU - Lee, Ji Hwan
AU - Koh, Hyoung Jun
AU - Byeon, Suk Ho
AU - Kim, Sung Soo
AU - Kim, Min
AU - Lee, Christopher Seungkyu
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose: To investigate whether subfoveal choroidal thickness predicted treatment response to anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Methods: This retrospective observational case series included 66 eyes of 60 patients who were diagnosed with new-onset PCV and who were followed for a minimum of 6 months. Patients received three monthly intravitreal injections of 0.5 mg ranibizumab or 1.25 mg bevacizumab, at baseline, month 1, and month 2. “Good responders” were defined as those who showed complete resolution of subretinal and/or intraretinal fluid at month 3 after the loading injections, whereas “poor responders” were defined as those who showed persistent retinal fluid on optical coherence tomography (OCT) at month 3 after treatment. Differences in best-corrected visual acuity, indocyanine green angiography, and spectral domain-OCT findings at baseline were analyzed between the two groups. Results: The mean patient age was 68.2 ± 9.7 years, and the mean follow-up period was 27 ± 21 months. The mean subfoveal choroidal thickness was 273 ± 117 μm, and choroidal vascular hyperpermeability was observed in 35 eyes (53.0 %). Thirty-three eyes (50 %) showed good response to treatment, and a thinner subfoveal choroid at baseline significantly correlated with favorable treatment response (P = 0.024). However, there was no significant relationship between treatment response and choroidal vascular hyperpermeability (P = 0.999). Conclusions: The subfoveal choroid was found to be significantly thinner among patients who achieved complete resolution of macular exudation after three loading injections of anti-VEGF agents.
AB - Purpose: To investigate whether subfoveal choroidal thickness predicted treatment response to anti-vascular endothelial growth factor (VEGF) in polypoidal choroidal vasculopathy (PCV). Methods: This retrospective observational case series included 66 eyes of 60 patients who were diagnosed with new-onset PCV and who were followed for a minimum of 6 months. Patients received three monthly intravitreal injections of 0.5 mg ranibizumab or 1.25 mg bevacizumab, at baseline, month 1, and month 2. “Good responders” were defined as those who showed complete resolution of subretinal and/or intraretinal fluid at month 3 after the loading injections, whereas “poor responders” were defined as those who showed persistent retinal fluid on optical coherence tomography (OCT) at month 3 after treatment. Differences in best-corrected visual acuity, indocyanine green angiography, and spectral domain-OCT findings at baseline were analyzed between the two groups. Results: The mean patient age was 68.2 ± 9.7 years, and the mean follow-up period was 27 ± 21 months. The mean subfoveal choroidal thickness was 273 ± 117 μm, and choroidal vascular hyperpermeability was observed in 35 eyes (53.0 %). Thirty-three eyes (50 %) showed good response to treatment, and a thinner subfoveal choroid at baseline significantly correlated with favorable treatment response (P = 0.024). However, there was no significant relationship between treatment response and choroidal vascular hyperpermeability (P = 0.999). Conclusions: The subfoveal choroid was found to be significantly thinner among patients who achieved complete resolution of macular exudation after three loading injections of anti-VEGF agents.
UR - http://www.scopus.com/inward/record.url?scp=84949521646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949521646&partnerID=8YFLogxK
U2 - 10.1007/s00417-015-3221-x
DO - 10.1007/s00417-015-3221-x
M3 - Article
VL - 254
SP - 1497
EP - 1503
JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie
SN - 0065-6100
IS - 8
ER -